More Articles

Acceptable changes in quality for glycosylated biologicals Biosimilars/Research | Posted 06/05/2011

Research carried out by Sandoz into three glycosylated protein biotechnology drugs currently on the market showed quality changes over the period studied. Since all three drugs remained on the mark...

Opportunities for biosimilar development Biosimilars/Research | Posted 06/05/2011

Rising drug costs and limited healthcare budgets across the world, coupled with the fact that many biotechnology drugs will soon lose their patent protection, means that there is a huge opportunity...

Savings due to generic substitution in South Africa Generics/Research | Posted 06/05/2011

A retrospective analysis of medical claims for antidepressants during 2004–2006 in South Africa calculated potential savings of 9.3% of the actual antidepressant cost over the study period.

US patent reform legislation may delay generics Policies & Legislation | Posted 06/05/2011

Generic drugmakers have been dealt a blow in Congress now that the Senate has passed patent-reform legislation despite efforts by the generics industry to remove a provision in the bill.

EGA meeting London 2011: biosimilars competitiveness in the EU Conferences | Posted 06/05/2011

At its 9th International Symposium on Biosimilar Medicines held in London, UK, on 14-15 April 2011 the European Generic medicines Association (EGA) highlighted the need for an EU industrial policy...

Generic prices in Australia slashed Generics/News | Posted 06/05/2011

In response to an article by Professor Philip Clarke in the Australian Financial Review titled Time to slash cost of generics, Medicines Australia Chief Executive Dr Brendan Shaw hit back saying th...

Teva grabs biopharmaceutical company Cephalon Biosimilars/News | Posted 06/05/2011

On 2 May 2011, Teva and Cephalon announced that they had unanimously approved a definitive agreement under which Teva will acquire all outstanding shares of Cephalon for US$81.50 per share in cash,...

Biobetters rather than biosimilars Biosimilars/General | Posted 06/05/2011

‘Biobetters’, rather than biosimilars, are the next big opportunity for biopharm and contract research organisations (CROs) hoping to profit from patent expirations on biologicals, say experts.